Keywords: Astellas, Ambit Biosciences, FLT3 kinase inhibitors, Licensing

Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million

Article | 18 December 2009

Leading Japanese drugmaker Astellas Pharma has entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications developed by USA-based privately held firm Ambit Biosciences, in a deal that could generate as much as $390 million for the latter.

Specifically, under the terms of thedeal, Ambit will receive an up-front cash payment of $40 million and will be eligible to receive pre-commercialization payments of up to $350 million. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in